Member Info for PM2022

I will quickly respond since I have looked at it quickly. All I will say regarding Cenkos is that VAL needed to complete the 201 deal. All they could do was introduce. We never had enough at the time for any ii to invest with. II have a different risk profile when it comes to investing than we do.

Ii will want revenue they don't tend to invest in high risk high reward stocks which are most AIM stocks. But if we can demonstrate the potential to get large deals and revenue and get 201 over the line then I believe they will. Huge incentive for them. As a business they will make more money than they can make from anywhere in many years if VAL hits 100p. They have no reason to sell it immediately. Complete nonsense that is like saying I don't want millions of pounds and throwing it in the bin.

Cenkos will come to the party later once we go above 22p. I like the Cenkos deal and agree Suzy made a good call with this.

We are expecting an increased cash burn but it's not much. We will have saved a considerable amount from in-house projects and the lab will be paid by revenue as confirmed by email from Suzy recently. Therefore I would expect the share price to be stable or increase but it all depends how they present it. The increase in cash burn is the period between revenue generation and setting up the lab and this is already known so priced in.

Porky you know all this so stop twisting my posts. You will not win with the Cenkos arguments.

Porky I don't even read your long posts. Waste of time because you're a known bull chitter and not to be trusted.

My points were valid and if someone offered you about £50k pounds per penny it would go up you would throw everything at it to make it work. That would be approx 5 million pounds for 120p share price. I might be wrong with my calculations but from memory. You would beg every ii in the country to get in. I would as you say it's business.

Hello Nick,

Since you always go on about Cenkos I would love to understand your thoughts and opinions on them.

1) Can you confirm how much Cenkos would make above 22p for every 1p, 10p, 50p? Do you think that any business will not want to make a few million pounds of profit? Note at this moment of time they have not paid for the warrants and don't have to do anything until it is time. Also if they benefit we benefit provided they work for it which is not proven yet.

2) Can you guarantee to every shareholder that Cenkos will not bring any II to Valirx in the next 1-2 years?

3) Do you believe any Ii would invest in a company with legacy compounds and old patents and no revenue or completed deals. Do you now believe that we will be more investible for II if we have a few in SPV with numerous chances of a huge deal, revenue and 201 deal IF it is completed. Note I have stated IF because I believe it will get done and you don't but let us assume it does get done.

The point I am making is that I think it is wrong to be critical of the Cenkos deal because in the end I believe they will really make the stock price really high when the foundations are in place. I think that means 201 deal and one more in SPV and at least a start with some revenue so at the moment it is difficult to say if it was a good move or bad.

If VAL gets cash from Cenkos then I would rather them have it than us diluting by another 6 per cent on the market at those prices for the same amount of cash through a placing. In the end it makes no difference but we have an extra chance that they may come hungry to drive us up and maximise profits.

I don't see the issue with that part but I can criticise how 201 has been handled so far due to a lack of information but I agree with it proceeding though. It's over to Suzy to build some confidence.

I would love to hear why you seem to think why Cenkos would bring II to VAL with just legacy drugs 201, 301 and 401 and zero revenue. It's a long term play for them. The foundations are set NOW. People like you lack the ability to see two minutes past the day. Nothing but followers. Use your own brain.

Cenkos was a great deal imo but it's down to Suzy to show everyone what they have done or what the plans are because when they want to make money and bring ii then you watch the share price move.

Sootysnipes,

Go and post on your OSI board. Loser.

Barcelona was due in Feb and we had no notification of failure or delay. It's due but probably setting up the SPV just like Kings which takes time.

I would rather have lots of news in a short space of time to create strong momentum. They will all want to go into the June votes with a bang.

Think 201, Barcelona, lab updates maybe even 301 and Hokkaido just before the votes. How things can change quickly.

As it stands I believe we are likely to get taken over for maybe £1 plus if we are not fair value by next year.

If Barcelona goes into SPV and 201 gets done. Then we have two SPV possibly 3/4 with Hokkaido and 301 by June. With the assets we have and if 201 gets done with a potential payment of £65 million plus royalties that alone would cover our buy out fee by a large pharma of £1 plus if that gets to market.

Any big Pharma would then get all our assets CLX, 301 hopefully with new patents, Barcelona and Hokkaido all for free and just offer us £1 next year. Obviously it would be a ten bagger from here and needs to be approved by shareholders. This is why it is important we reach fair value as we are at risk of a decent offer coming through to take us over in the next year or so.

If Barcelona goes into SPV we should be 35p imo. In Adam's professional opinion CLX is worth 15-20p at the moment then 10p for Barcelona and we got a lab. That is not even including Hokkaido, 301 or 201.

If we are not 35 p if Barcelona goes into SPV then we are at risk of a takeover offer of £1 range by a big pharma in the next year or so. So many possibilities so the only way is up from here imo. We will eventually attract investment if we generate revenue or if we remain undervalued. One large buyer Adam's size suddenly takes us to 30,40,50p fairly easily. You always end up at fair value if you control dilutions so a great buy here.

I'm glad you're bullish long term. All I am saying is that you don't have any facts regarding TRX. We know that it has caused us to drop and has been handled badly but now it's not priced in and IF it comes good soon then we will rise significantly from here. Even with an update we could have a significant rise.

Anyway if ever a time to be positive I would argue it is now given the amount of pending news. Sorry but people work towards deadlines in life and TRX/ BOD would also be doing this. Not saying it will be reached but for sure they would be targeting 201 news this month or in May and this target would have been in place since last year.

For now Barcelona is due and I think it will be more valuable than 201 if it goes into SPV. I am sure you agree not much downside but upside over 2 years could be anything including £2/£3.

We are 9p-20p range although more recently 9p-13p without news but that is no longer relevant. Now that news is due over the next 6 weeks that all goes out the window and it's time to buy imo. I agree with Patient AIM is all news driven so NOW would be a great time to buy ahead of news.

Nick, you have reduced your holdings significantly. Therefore although some of what you say is true, I cannot trust your agenda at this moment of time. Why not give it until the end of May unless you are desperately trying to buy in.

In the next 6 weeks we should have the following news taking us to a much higher price:

1) Val 201 deal/update
2) lab news possible contracts
3)Barcelona SPV due now
4) 301 news
5) Hakkaido in June
6) Possible II or BOD buying in before June votes

Raising later in the year is not an issue if you are at a better SP. Given the news that is due I am sure we will be. Our spending remains very low for an AIM pharma as we do not conduct clinical trials.

I have been here long enough to now be happy with what I have but if it does drop below 9p then I may add more but I think we are now at the bottom given the amount of news due.

Anyway I am sure they have it planned and know the timetable. To suggest otherwise is not logical so we shall see how it plays out.

It's been handled badly so far given the SP so it's on them to provide an update or complete by June.

Clearly the 201 deal being completed is what is right unless you have alternatives and given the reasons it might not be the case so it's a deal or no deal. It's not for us to judge what is happening unless we know the facts but we just need clarity. Happy to wait a little longer past June provided they give some details.

As I said I don't listen to anyone here as everyone has an agenda. Some have sold and want a cheaper entry so the right answer is to complete or get an update with at least some information/timings or payment by June. The rest is nonsense about wanting to withdraw exclusivity as any alternative is not going to be quick and that is if we ever get one. If none of the above is done then eventually they will have to withdraw if it is not close and they are not prepared to update us but I would say June would be the latest for that.

It's hard to see a conspiracy here so I am 95% it will get done but timings I have no idea.

The only information you have at the moment is what the BOD has said therefore you have to take it at face value unless you have evidence to suggest otherwise. Taking two years is not enough of a reason to say the deal will not happen. How do you know how much they are raising or how many other compounds they are dealing with or whether they are trying to get listed?

I am not saying we should not get an update or a payment but I disagree with removing exclusivity for the sake of it. If they are very close or can reach a compromise with an update then that is what is best for the company, shareholders and patients.

I think BOD needs to be balanced. So if Stella holds zero shares then ideally Adam should be on the board if he wants or another major shareholder who is not trading the stock and wants a genuine increase in the SP. But if Stella buys in a fair amount or Suzy or Kevin add a fair amount then they can continue as is provided they can demonstrate what they are doing with the SP. I think that is fair.

Look we need an update that I agree with. I can see why TRX was picked though and in the long run the real value would be with the new patents for another 20 years. That would bring huge value to the drug.

You say it's only worth what people will pay for it. Well at the moment the issue is that because it's a legacy drug it needs a bit of work but as long as they secure funding which is one of the most difficult part of drug development then a number of factors do get priced in. TRX got a good deal and with the skills (patents) that they have all the more reason why the 201 deal will get done as any investor investing with TRX will likely see huge returns. Not a great deal for us but it is what it is but relative to our MC it would still add substantial value. I stand by my MC value and it's also proven by previous price movements.

Anyway we are priced at zero for 201 so what does it matter at the moment. CLX, Barcelona and lab alone we should be 30p therefore expecting a significant move up if Barcelona moves to SPV.

Personally 201 is a bonus but a great bonus at 0p for anyone investing knowing it could add an instant 20,30 or 40p to our SP. Maybe 1-2p downside here but 200-300p upside from current SP in the next two years if you look at numerous late stage pre-clinical deals. Having more in SPV means more likely a deal gets secured and hopefully one fairly early.

Progress that is monitored by BOD for 201 which they have confirmed that they have evidence and have been monitoring closely. Down to people if they believe that but I do because it would be criminal if it was a deliberate lie to the market.

Absolute nonsense. Which shareholder would vote for us to get taken over at the current SP. I would suggest an offer of at least 65p for it to be accepted so you are talking rubbish again. Besides, the 65 million odd is not payable now but after the clinical trials so why would they make an offer now. Once they file the patents for 201 and do the trials then it will be worth 100s million if it passes. At that point they can take us over but we will be a much higher SP and they will not be able to afford us.

As Adam has already told you 100 times AZ and most other pharma cannot take the drug at the moment as most don't have the expertise to repatent the drug and we need more data which is what phase two trials will generate. Still given we have spent more 20 million on 201, had promising results, made it through early stages and with the potential of getting around 65 million plus royalties every year then it should add about 30-35p to our SP immediately if the deal is concluded.

I would have to say I am 95% sure the 201 deal will get completed. A few here just want the deal pulled so they can buy 1-2p cheaper which is shameful. I just don't see how after 2 years where progress has been monitored that they would lie to the market with the entire board involved plus others that may know like legal teams and so on. Just not reality but obviously it can fail but given progress so far that is unlikely.

If you really don't want to buy in then I don't see why you spend all your time here everyday and you're not invested. Just don't trust anything you say. 10p Is real value and I think desperation is a telling factor here.

Come on Suzy time to get RNS out and leave these trolls behind. Lots of news due. I think Barcelona if it goes to SPV will be more valuable than 201 over a period of time. Looking forward to the next few weeks and like you say Porky you will not post here for a while.

Not sure where the 8p comes from as we have not been that price for years. Expecting lots of news now and momentum to build. I would be buying to avoid missing out. GL all.

Probably a distraction from the reality of losing money in DDDD and he likes attention. He has been saying he will invest for the last 2 years. First he stated if VAL got new BOD members and staff that he will support them then it was the previous placings now the next one. VAL was 9p and he never purchased but he was ramping at 50p saying it will go to 150p. The reality is he has no money and is trying to make us think he has it invested somewhere else but that is nonsense. If he is this desperate he would have purchased already at these prices.

The 201 deal can still happen very soon and the company has progressed, in a few weeks we could have 1-4 SPVS if you include 301 plus a lab generating revenue yet he thinks we are not cheap at 10 million. We never had this before. Personally I think Barcelona going into SPV will carry more value than if the 201 deal was completed because as it progresses then the likelihood of a future large deal gets priced in more as it moves forward along with other SPVs.

Expecting news this week and a busy 4-6 weeks ahead and a decent re-rate on the cards.

Don't see the relevance as according to you everything is zero until it gets commercialised. Therefore 55% of zero is zero so is 100% of zero but I would take a deal which would take us up considerably from current SP for 401 or anything else with 55% ownership.

Or they could have sold at 65p or 74p in the last 2/3 years or purchased at those prices as well. Every stock has highs and lows but I would say given that we have moved forward in so many ways that we should be at least 30p by now even in the current market.

The next 4 weeks will tell us where we go but I would not listen to anyone not invested.

Waynesmith,

I think the lab is a good move. They want a number of evaluations to come through and that just speeds up the process and is more cost effective. Suzy also mentioned to get big institutional investors to invest they ideally need revenue. An early deal for the preclinical drugs is not guaranteed plus it will hopefully eliminate big placings in the future.

Everyone knows we are oversold here. My view is that we have two very big news coming from now to June. Barcelona being the first one. If that goes into SPV along with CLX which we have and 301 and possibly Hokkaido then we have 3/4 SPV. You would fancy your chances of at least one getting a deal or late stage preclinical in the next 18 months. That would likely mean 100-300 million market cap and we are only 10 million at the moment. Look at SAR based on one compound and it hit 300 million market cap at one stage. The potential will get priced in even if it just takes us to 20-25 p when Barcelona SPV is announced.

201 is the second big news. My view is that they could have pulled the deal during the last update. Given it has taken two years and progress has been monitored then it's on for sure. This is backed with the opinion of the entire board including Stella. I would have thought they would all want this concluded by June even TRX as if new management came if they could pull the deal and it would be 2-3 years a waste of time for TRX. Suzy and Stella would have made the deadline clear to them and that deadline would be the end of April. I think the end of May would be very late. So we could hear end of April or first half of May regarding 201.

I am giving 201 and Barcelona an 80-90% chance of coming good by June. Barcelona looks highly likely as if it had failed or was delayed we likely would have known by now. It looks like they are setting up the SPV. We have so much other news not priced in. Therefore an easy multibagger imo. My two year target is £2 but I might reduce it to £1 depending on outcomes and progress in the coming months.